Adding antibody treatment to chemo boosts outcomes for children with rare cancer
Date:
Children with a rare form of cancer called neuroblastoma which hasn’t responded to initial treatment, or that has relapsed, may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical trial.
The BEACON phase 2 trial was carried out by an international team of researchers – coordinated by the University of Birmingham’s Cancer Research UK Clinical Trials Unit, with research led by Professor Juliet Gray at the University of Southampton and University Hospital Southampton.
Read the full article here.
